Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.11 -0.9%	$2.11	$1.43 ▼ $3.98	$210.36M	1.65	157,543 shs	73,397 shs
HRTX Heron Therapeutics	$1.31 -1.9%	$1.93	$1.04 ▼ $2.68	$200.04M	1.15	1.68 million shs	1.53 million shs
KRON Kronos Bio	$0.88 +1.5%	$0.81	$0.65 ▼ $1.46	$53.72M	1.64	370,931 shs	54,089 shs
MNPR Monopar Therapeutics	$35.06 -1.8%	$38.02	$2.15 ▼ $54.30	$216.29M	1.05	39,496 shs	20,928 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-0.47%	+2.90%	+22.41%	-36.80%
HRTX Heron Therapeutics	0.00%	+0.76%	-31.09%	-30.73%	-31.09%
KRON Kronos Bio	0.00%	0.00%	0.00%	+30.76%	-11.95%
MNPR Monopar Therapeutics	0.00%	+3.06%	-23.17%	-3.22%	+1,432.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	1.6539 of 5 stars	3.5	1.0	0.0	0.0	1.5	0.8	0.6
HRTX Heron Therapeutics	4.1437 of 5 stars	3.2	1.0	0.0	4.2	3.4	3.3	0.6
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.8628 of 5 stars	3.4	4.0	0.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	468.72% Upside
HRTX Heron Therapeutics	2.33	Hold	$4.50	244.83% Upside
KRON Kronos Bio	2.33	Hold	$1.63	84.66% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	71.16% Upside

Current Analyst Ratings Breakdown

Latest KRON, ACIU, MNPR, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.83	N/A	N/A	$1.29 per share	1.64
HRTX Heron Therapeutics	$144.29M	1.39	N/A	N/A	($0.22) per share	-5.93
KRON Kronos Bio	$9.85M	5.45	N/A	N/A	$1.45 per share	0.61
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-174.94%	-49.35%	-23.16%	11/4/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	N/A
KRON Kronos Bio	-$86.08M	-$1.07	N/A	N/A	N/A	-701.53%	-64.22%	-47.17%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	N/A

Latest KRON, ACIU, MNPR, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/5/2025	Q2 2025	ACIU AC Immune	-$0.20	-$0.25	-$0.05	-$0.25	$1.98 million	$1.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.33	1.33
HRTX Heron Therapeutics	N/A	0.82	0.53
KRON Kronos Bio	N/A	12.93	12.93
MNPR Monopar Therapeutics	N/A	33.93	33.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
HRTX Heron Therapeutics	80.01%
KRON Kronos Bio	64.09%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
HRTX Heron Therapeutics	5.86%
KRON Kronos Bio	24.40%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
KRON Kronos Bio	100	61.05 million	46.16 million	Optionable
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable

KRON, ACIU, MNPR, and HRTX Headlines

Recent News About These Companies

MNPR FY2025 EPS Lifted by Brookline Capital Management

August 17 at 10:02 AM | marketbeat.com

Cantor Fitzgerald Analysts Cut Earnings Estimates for MNPR

August 17 at 10:02 AM | marketbeat.com

FY2025 EPS Estimate for Monopar Therapeutics Cut by Analyst

August 17 at 2:46 AM | americanbankingnews.com

Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Chardan Capital

August 15 at 5:26 PM | marketbeat.com

Chardan Capital Reiterates "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)

August 15 at 2:51 AM | americanbankingnews.com

Monopar Therapeutics (NASDAQ:MNPR) Announces Earnings Results, Beats Expectations By $0.12 EPS

August 13, 2025 | marketbeat.com

Monopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 13, 2025 | finanznachrichten.de

Monopar Therapeutics Reports Increased R&D Expenses

August 13, 2025 | msn.com

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12, 2025 | manilatimes.netM

Monopar Therapeutics Inc. Reports Q2 2025 Financial Results and Progress on ALXN1840 and MNPR-101 Clinical Trials

August 12, 2025 | quiverquant.comQ

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12, 2025 | globenewswire.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of "Moderate Buy" from Analysts

August 12, 2025 | marketbeat.com

Monopar Therapeutics (MNPR) Projected to Post Earnings on Friday

August 1, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from Analysts

July 18, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim R. Tsuchimoto Sells 8,904 Shares

July 17, 2025 | insidertrades.com

Cantor Fitzgerald Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation

July 8, 2025 | msn.com

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

June 26, 2025 | finance.yahoo.com

Institutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)

June 23, 2025 | finance.yahoo.com

Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation

June 23, 2025 | msn.com

Monopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | finanznachrichten.de

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

June 11, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRON, ACIU, MNPR, and HRTX Company Descriptions

AC Immune NASDAQ:ACIU

$2.11 -0.02 (-0.94%)

As of 03:08 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Heron Therapeutics NASDAQ:HRTX

$1.30 -0.03 (-1.88%)

As of 03:09 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Kronos Bio NASDAQ:KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Monopar Therapeutics NASDAQ:MNPR

$35.06 -0.66 (-1.83%)

As of 03:09 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time